Allergy & Immunology

Developed Formulas
  • Supports a healthy immune system

  • Helps prevent infections

  • Antipathogenic activity

Allergy & Immunology
Ready to market
Allergy & Immunology
Clinical test
Allergy & Immunology
Allergy & Immunology
In vitro test
Allergy & Immunology
Hydrosoluble powder
Allergy & Immunology
Allergen Free
Allergy & Immunology
Real time stability

Bifidobacterium lactis BS01 (LMG P-21384)
Lacticaseibacillus rhamnosus LR04 (DSM 16605)
Lactiplantibacillus plantarum LP02 (LMG P-21020)
Fructooligosaccharides (FOS)

Label Claim
Effective nutraceutical combination
Scientific Rationale

Over the past decade, numerous studies have highlighted the vital role of the gastrointestinal tract. It is not solely responsible for digesting and absorbing nutrients but also serves as the primary organ of the immune system, hosting approximately 70% of our defenses. Specifically, the intestinal bacterial flora plays a central role in developing and modulating the immune system. Bifidobacterium lactis BS01, Lacticaseibacillus rhamnosus LR04, and Lactiplantibacillus plantarum LP02, all featured in BIFIMMUN®, contribute significantly to supporting immune system function and safeguarding the body from pathogenic factors. These strains have demonstrated notable activities related to the immune system. BIFIMMUN® has undergone testing in both in vitro and clinical studies, consistently showing its ability to fortify natural defenses and effectively prevent winter diseases. Specifically, it has been proven to:

  • Inhibit intestinal and respiratory pathogens, including Klebsiella pneumoniae and Pseudomonas aeruginosa.

  • Strengthen natural defenses by stimulating the appropriate immune cell types. Indeed, BS01 has demonstrated its capacity to stimulate the proliferation of Peripheral Blood Mononuclear Cells (PBMCs) and the differentiation of macrophages into Dendritic Cells (DCs) [1, 3]. Additionally, both BS01 and LR04 can stimulate the proliferation of Natural Killer cells (NKs), which can identify infected or altered cells and induce cytolysis[3]. BS01 also induces significant pro-inflammatory cytokines essential for combating viral and microbial pathogens, including IL12p70, TNFα, IFNα, and IFNγ[3].

In a clinical study [4], the administration of BIFIMMUN® for 90 days led to a significant reduction in the prevalence, severity, and duration of flu episodes, upper respiratory tract infections, and acute respiratory infections, often by a factor of 50%.


1. Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.doi: 10.1097/MCG.0000000000001068

2. Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7

3. Internal Probiotical Data

4. Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233. DOI: 10.1097/MCG.0b013e31817e1c91